Last updated: May 5, 2026
Litigation Summary and Patent Analysis: Alnylam Pharmaceuticals, Inc. v. Pfizer Inc. | 1:22-cv-00336
What is the case and who are the parties?
- Case: Alnylam Pharmaceuticals, Inc. v. Pfizer Inc.
- Court / docket: 1:22-cv-00336
- Filing year: 2022
- Parties: Alnylam Pharmaceuticals, Inc. (plaintiff) vs Pfizer Inc. (defendant)
- Core posture: Patent litigation involving alleged infringement by Pfizer against Alnylam’s claimed intellectual property in the RNAi / siRNA therapeutics space.
What claims and patents are at issue?
No complete, reliable case record content is present in the supplied information (the docket caption and case number alone do not identify: asserted patents, claim numbers, asserted products, infringement theories, invalidity grounds, or claim construction outcomes). Under the operating constraints, an accurate litigation summary cannot be produced without the underlying filing-specific details.
What did the parties allege?
The provided input does not include the operative complaint, infringement contentions, defenses, or any court orders. As a result, the following cannot be stated accurately:
- which Pfizer product(s) were accused
- which Alnylam patents were asserted
- which claim elements were alleged to be met
- whether the case alleged direct infringement, inducement, or contributory infringement
- whether Pfizer asserted invalidity (35 U.S.C. §§ 101, 102/103, 112), unenforceability, or non-infringement defenses
- whether any IPRs or PTAB proceedings intersect the case
What procedural events matter for valuation and risk?
A litigation-risk and value-impact analysis depends on the litigation timeline and the court’s rulings (e.g., motion to dismiss, claim construction, summary judgment, preliminary injunction, discovery milestones, trial setting, settlement signals, or dismissal/termination). None of these data points are present in the supplied material.
How does this litigation fit the broader Alnylam vs. Pfizer IP pattern?
Broadly, Alnylam’s enforcement posture in RNA interference is commonly tied to platform IP around:
- siRNA molecule design and chemical modification approaches
- formulation and delivery strategies
- target engagement / mechanism-specific claims
- methods of treatment
But without case-specific identification of patents and the asserted claims, it is not possible to map the docket to a defined patent family, expiration profile, or enforceability status.
Patent landscape checkpoints (what a complete analysis would include)
A credible patent and litigation analysis for this docket would normally enumerate, for each asserted patent:
- Publication / patent number and assignee
- Priority date(s) and earliest non-provisional filing
- Claim scope relevant to the accused subject matter
- Expiry / PTA status (and any terminal disclaimer terms)
- Claim construction outcomes (especially for dispositive terms)
- 101 posture (eligibility) and any Federal Circuit implications
- Invalidity posture (anticipation/obviousness references)
- Enforcement posture (standing, estoppel, or related proceedings)
- Remedies sought (injunctive relief vs damages only; willfulness allegations)
The necessary docket-specific data is not provided, so none of the above can be populated in a way that would be accurate.
What is the likely business impact (in the absence of docket specifics)?
Business impact can be inferred only at a generic level when the case record is not available. For decision-making, you need:
- whether the court narrowed claims during Markman
- whether Pfizer has a non-infringing design-around that avoids the asserted claim limitations
- whether the asserted patents are early- or late-stage in terms of enforceability and expiration
- whether the asserted patents intersect the product profile with specific delivery chemistry or dosing regimens
These are not available from the input.
Bottom line
With only the case caption and docket number, this request cannot be completed into a “hard data” litigation summary and patent analysis without inventing or guessing missing case-specific facts, which would violate the accuracy requirement embedded in the operating constraints.
Key Takeaways
- The docket identified is Alnylam Pharmaceuticals, Inc. v. Pfizer Inc., 1:22-cv-00336.
- The provided input does not include the operative complaint, asserted patents, claim terms, accused products, procedural rulings, or dispositive orders.
- A litigation summary and patent analysis that is accurate and decision-grade cannot be produced from the supplied information.
FAQs
-
What patents are asserted in 1:22-cv-00336?
Not determinable from the provided input.
-
What Pfizer product(s) are accused?
Not determinable from the provided input.
-
Has the court issued a Markman (claim construction) ruling in this case?
Not determinable from the provided input.
-
Is there an injunction, summary judgment, or dismissal order in the docket?
Not determinable from the provided input.
-
Are there related PTAB IPRs tied to the asserted patents?
Not determinable from the provided input.
References (APA)
- Alnylam Pharmaceuticals, Inc. v. Pfizer Inc., No. 1:22-cv-00336 (Docket information referenced only by case number and caption as provided by user).
